About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Until 2017, this group was constituted as a consolidated group in the VHIR under the name of "Digestive Transplants" with a consolidated research trajectory. Our group has two large areas of research: liver transplantation, which is cross-sectional adult-pediatric and; on the other hand, research, specifically in the fields of liver resections, liver cancer (primary or metastatic), biliary cancer, pancreatic cancer and pancreatitis. Both areas have very innovative aspects, with translational objectives, including artificial intelligence, transcriptomics and molecular biology.
The general objective of the liver transplant research area is to improve the preservation of liver grafts, as well as increase the survival of grafts and transplant patients. The research area related to cancer or acute pancreatitis has as a general objective to improve the management and treatment of patients with pancreatitis, as well as to improve the diagnosis and survival of cancer patients.
L'objectiu comprendre els tipus de microbiota intestinal en pacients cirròtics des del dia en què figuren en llista d'espera per al trasplantament hepàtic fins al primer any després del trasplantament.
IP: Itxarone Izaskun Bilbao Aguirre, Cristina Dopazo Taboada
L'objectiu es si existeix un perfil d'expressió diferencial entre donants, així com un biomarcador objectiu i precís de la viabilitat de l'empelt.
IP: Ramon Charco Torra, Mar Dalmau Romero, Concepción Gomez Gavara
Rol de la endoscòpia en el tumor primari per la detecció de perfil genètic tumoral.
IP: Elizabeth Pando Rau, Joaquin Balsells Valls
IP: Ernest Hidalgo Llompart, Mireia Caralt Barba
IP: Concepción Gomez Gavara Collaborators: Itxarone Izaskun Bilbao Aguirre Funding agency: Instituto de Salud Carlos III Funding: 90200 Reference: DTS22/00178 Duration: 01/01/2023 - 31/12/2024
IP: Juan Ignacio Esteban Mur Collaborators: Lluís Viladomiu Catà, Silvia Sauleda Oliveras, Jordi Llaneras Artigues, Marta Bes Maijo, Cristina Dopazo Taboada, Angie Rico Blazquez Funding agency: Instituto de Salud Carlos III Funding: 159720 Reference: PI19/00533 Duration: 01/01/2020 - 30/06/2024
IP: Isabel Campos Varela Collaborators: Lluis Castells Fusté, Nuria Roson Gradaille, Ernest Hidalgo Llompart Funding agency: Instituto de Salud Carlos III Funding: 84095 Reference: PI19/00330 Duration: 01/01/2020 - 30/06/2024
IP: Beatriz Minguez Rosique Collaborators: Itxarone Izaskun Bilbao Aguirre, Elena Vargas Accarino, Torrens Buscató, Maria Margarita, Maria Teresa Salcedo Allende, Monica Higuera Urbano Funding agency: Instituto de Salud Carlos III Funding: 183920 Reference: PI21/00714 Duration: 01/01/2022 - 31/12/2024
PMID: 37989543 Journal: ANNALS OF THE RHEUMATIC DISEASES Year: 2023 Reference: Ann Rheum Dis. 2023 Nov 21:ard-2023-225042. doi: 10.1136/ard-2023-225042. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Alijotas-Reig, Jaume; Anunciacion-Llunell, Ariadna; Barrios, O; Dopazo, C; Esteve-Valverde, Enrique; Fundora, Suarez Y; Gomez-Gavara, C; Llado, L; Lopez-Boado, M; Marques-Soares, Joana et al. DOI: 10.1136/ard-2023-225042
Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.
Vall d'Hebron professionals presented four posters, two oral communications and two lectures by Dr. Dopazo and Dr. Gomez-Gavara.
The donation will go towards two studies aimed at improving the quality of life of paediatric liver transplant patients.
